GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cash Flow from Others

Agenus (FRA:AJ8) Cash Flow from Others : €5.3 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Cash Flow from Others?

Agenus's cash flow from others for the three months ended in Sep. 2024 was €7.2 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2024 was €5.3 Mil.


Agenus Cash Flow from Others Historical Data

The historical data trend for Agenus's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Cash Flow from Others Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.88 14.17 19.69 -0.19 -12.82

Agenus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -7.93 2.73 3.29 7.20

Agenus Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.3 Mil.

Agenus Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Agenus's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Headlines

No Headlines